Priority Medicines for Europe and the World
暂无分享,去创建一个
[1] Carl T. Bergstrom,et al. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[2] K. Ko,et al. High Prevalence of Antimicrobial Resistance among Clinical Streptococcus pneumoniae Isolates in Asia (an ANSORP Study) , 2004, Antimicrobial Agents and Chemotherapy.
[3] H. Mobley,et al. Development of an Intranasal Vaccine To Prevent Urinary Tract Infection by Proteus mirabilis , 2004, Infection and Immunity.
[4] A. Voss,et al. Controlling glycopeptide-resistant enterococci. , 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[5] V. Fischetti,et al. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] B. Chabner,et al. Beyond fast track for drug approvals. , 2004, The New England journal of medicine.
[7] K. Ekdahl,et al. Previous Antibiotic Consumption and Other Risk Factors for Carriage of Penicillin-Resistant Streptococcus pneumoniae in Children , 1998, European Journal of Clinical Microbiology and Infectious Diseases.
[8] D. Shlaes,et al. The United States Food and Drug Administration and the end of antibiotics. , 1935, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Larkin. Daptomycin approved for skin and skin-structure infections , 2003 .
[10] I. Okeke,et al. Socioeconomic and behavioral factors leading to acquired bacterial resistance to antibiotics in developing countries. , 1999, Emerging infectious diseases.
[11] M. Kelsey,et al. The Second National Prevalence Survey of infection in hospitals--overview of the results. , 1996, The Journal of hospital infection.
[12] G Sherman,et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. , 1999, Chest.
[13] D. Haldane,et al. Comparison of the Velogene Rapid MRSA Identification Assay, Denka MRSA-Screen Assay, and BBL Crystal MRSA ID System for rapid identification of methicillin-resistant Staphylococcus aureus. , 2001, Diagnostic microbiology and infectious disease.
[14] F. M. Stewart,et al. The population genetics of antibiotic resistance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] J. Verhoef,et al. Frequency of Isolation and Antimicrobial Resistance of Gram-Negative and Gram-Positive Bacteria from Patients in Intensive Care Units of 25 European University Hospitals Participating in the European Arm of the SENTRY Antimicrobial Surveillance Program 1997–1998 , 2001, European Journal of Clinical Microbiology and Infectious Diseases.
[16] S. Black,et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.
[17] T. Ida,et al. CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa , 2002, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[18] D. Andersson,et al. Persistence of antibiotic resistant bacteria. , 2003, Current opinion in microbiology.
[19] G. Leverson,et al. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. , 2003, The Journal of urology.
[20] K. Bush,et al. Novel antibacterial agents for the treatment of serious Gram-positive infections. , 2003, Expert opinion on investigational drugs.
[21] F. Rodríguez Sánchez,et al. [Rational use of antibiotics in pediatrics: impact of a rapid test for detection of beta-haemolytic group A streptococci in acute pharyngotonsillitis]. , 2000, Anales espanoles de pediatria.
[22] M. Enright,et al. Vancomycin Susceptibility within Methicillin-resistant Staphylococcus aureus Lineages , 2004, Emerging infectious diseases.
[23] S. Projan,et al. Why is big Pharma getting out of antibacterial drug discovery? , 2003, Current opinion in microbiology.
[24] Mitchell L. Cohen. Epidemiology of Drug Resistance: Implications for a Post—Antimicrobial Era , 1992, Science.
[25] F. Vandenesch,et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] I. Phillips,et al. Antibiotic clinical trials—the Witley Park Symposium , 1999 .
[27] Rino Rappuoli,et al. Reverse Vaccinology and Genomics , 2003, Science.
[28] D. Shlaes. The abandonment of antibacterials: why and wherefore? , 2003, Current opinion in pharmacology (Print).
[29] R. Spencer,et al. Surveillance of antibiotic resistance in European ICUs. , 2001, The Journal of hospital infection.
[30] Thomas D Gootz. The current state of antibacterial research , 2003, Expert review of anti-infective therapy.
[31] D. Calfee,et al. Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] F. Baquero,et al. Strategies to minimize the development of antibiotic resistance. , 1997, Journal of chemotherapy.
[33] Clement S. Chu,et al. A New Class of Bacterial RNA Polymerase Inhibitor Affects Nucleotide Addition , 2003, Science.
[34] H. Endtz,et al. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. , 1991, The Journal of antimicrobial chemotherapy.
[35] M. Chapman,et al. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. , 2004, The Journal of urology.
[36] R. Jones,et al. Oxazolidinones: a review. , 2000, Drugs.
[37] R. Marples,et al. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16) , 1995, The Journal of hospital infection.
[38] J. Turnidge. Impact of Antibiotic Resistance on the Treatment of Sepsis , 2003, Scandinavian journal of infectious diseases.
[39] H. Neu,et al. The Crisis in Antibiotic Resistance , 1992, Science.
[40] J. Powers,et al. Trends in antimicrobial drug development: implications for the future. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] C. Merril,et al. The prospect for bacteriophage therapy in Western medicine , 2003, Nature Reviews Drug Discovery.
[42] J. Hendley. Clinical practice. Otitis media. , 2002, The New England journal of medicine.
[43] T. Shakya.,et al. Historical Introduction , 2002, Jewish Identities: Fifty Intellectuals Answer Ben-Gurion.
[44] Stephan Harbarth,et al. Antibiotic Selection Pressure and Resistance in Streptococcus pneumoniae and Streptococcus pyogenes , 2004, Emerging infectious diseases.
[45] B. Levin,et al. The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.
[46] K. Towner,et al. Detection of Methicillin-Resistant Staphylococcus aureus (MRSA) in Blood with the EVIGENE MRSA Detection Kit , 2003, Journal of Clinical Microbiology.
[47] C. Whitney,et al. Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. , 2004, Seminars in pediatric infectious diseases.
[48] J. Coast,et al. Over-the-counter antimicrobials: the hidden costs of resistance. , 1996, The Journal of antimicrobial chemotherapy.
[49] O. Cars,et al. Moving from recommendation to implementation and audit: part 1. Current recommendations and programs: a critical commentary. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[50] O. Cars,et al. Moving from recommendation to implementation and audit: part 2. Review of interventions and audit. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[51] R. Anderson,et al. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[52] J. Powers. Development of drugs for antimicrobial-resistant pathogens , 2003, Current opinion in infectious diseases.
[53] P. Youngman,et al. Antimicrobials: new solutions badly needed. , 2002, Current opinion in microbiology.
[54] D. Livermore. Can better prescribing turn the tide of resistance? , 2004, Nature Reviews Microbiology.
[55] S. Sullivan,et al. Economic Issues and Antibiotic Resistance in the Community , 2002, The Annals of pharmacotherapy.
[56] H. Haak. Determinants of Antimicrobial Use in the Developing World , 2002 .
[57] Vincent A. Fischetti,et al. Rapid Killing of Streptococcus pneumoniae with a Bacteriophage Cell Wall Hydrolase , 2001, Science.
[58] B. Levin,et al. The population dynamics of antimicrobial chemotherapy , 1997, Antimicrobial agents and chemotherapy.
[59] J. Hurley. Risk of death from methicillin‐resistant Staphylococcus aureus bacteraemia: a meta‐analysis , 2002, The Medical journal of Australia.
[60] A. Fattom,et al. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. , 2004, Vaccine.
[61] R. Anderson,et al. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[62] T. Nakamoto,et al. Evaluation of panipenem/betamipron (PAPM/BP) in pneumonia in elderly patients , 2002, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[63] F. Vandenesch,et al. Community-Acquired Methicillin-Resistant Staphylococcus aureus Carrying Panton-Valentine Leukocidin Genes: Worldwide Emergence , 2003, Emerging infectious diseases.
[64] P. François,et al. Rapid Detection of Methicillin-Resistant Staphylococcus aureus Directly from Sterile or Nonsterile Clinical Samples by a New Molecular Assay , 2003, Journal of Clinical Microbiology.
[65] A. Bruce,et al. Urogenital infections in women: can probiotics help? , 2003, Postgraduate medical journal.
[66] D. Livermore. Bacterial resistance: origins, epidemiology, and impact. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[67] Xiaoan Ruan,et al. Novel Antibacterial Class , 2003, Antimicrobial Agents and Chemotherapy.
[68] B. Levin,et al. Minimizing potential resistance: a population dynamics view. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] J. Coast,et al. Antimicrobial resistance: a global response. , 2002, Bulletin of the World Health Organization.
[70] Merrill Goozner,et al. The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .
[71] R. Giroux,et al. New Real-Time PCR Assay for Rapid Detection of Methicillin- Resistant Staphylococcus aureus Directly from Specimens Containing a Mixture of Staphylococci , 2004, Journal of Clinical Microbiology.
[72] Mary Jane Ferraro,et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus , 2001, The Lancet.
[73] Marc Lipsitch,et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States , 2003, Nature Medicine.
[74] S. Langermann,et al. Development of a recombinant FimCH vaccine for urinary tract infections. , 2003, Advances in experimental medicine and biology.
[75] O. Cars,et al. Suboptimal Antibiotic Dosage as a Risk Factor for Selection of Penicillin-Resistant Streptococcus pneumoniae: In Vitro Kinetic Model , 2003, Antimicrobial Agents and Chemotherapy.
[76] I. Phillips,et al. Antibiotic clinical trials revisited. , 2000, The Journal of antimicrobial chemotherapy.
[77] M. Kremer,et al. Perspectives on stimulating industrial research and development for neglected infectious diseases. , 2001, Bulletin of the World Health Organization.
[78] A. White. The Pharmaceutical Company Approach to Antibiotic Policies , 2005, Antibiotic Policies.
[79] M. P. Singh,et al. Antibacterial leads from microbial natural products discovery. , 2000, Current opinion in drug discovery & development.
[80] J. Powers,et al. Appropriate antimicrobial prescribing: approaches that limit antibiotic resistance. , 2001, American family physician.
[81] S. Cosgrove,et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[82] J. Kragstrup,et al. [Antibiotic treatment of infections in general practice. Effect of audit assessed by prescriptions data from health insurance registry and physicians' own registration]. , 2001, Ugeskrift for laeger.
[83] M. Hufnagel,et al. Enterococcal infections: host response, therapeutic, and prophylactic possibilities. , 2004, Vaccine.
[84] Robin Patel,et al. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. , 2002, The New England journal of medicine.
[85] Laura Nelson,et al. Defence work sheds light on hospital bacteria , 2004, Nature.
[86] How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[87] Stephan Harbarth,et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. , 2003, The American journal of medicine.
[88] M. Woolhouse,et al. What is antibiotic resistance and how can we measure it? , 2000, Trends in microbiology.